BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure
Stock Information for BioCardia Inc.
Loading
Please wait while we load your information from QuoteMedia.